A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

This study is testing different doses of a drug called bulumtatug fuvedotin in women with triple-negative breast cancer (a type that doesn't respond to hormone therapies) who have already been treated with another antibody-drug conjugate medication. **You may be eligible if...** - You are 18 or older - You have metastatic or recurrent triple-negative breast cancer - You have already received a taxane (such as paclitaxel or docetaxel) and at least one prior antibody-drug conjugate with a topoisomerase inhibitor payload - You have had no more than 3 prior chemotherapy regimens for advanced disease - You are in good overall health (ECOG 0–1) with adequate organ function and a life expectancy of at least 3 months - You have a tumor that can be biopsied or archived tissue available **You may NOT be eligible if...** - You have received more than 3 prior lines of chemotherapy for advanced disease - Your organ function or overall health is too poor Talk to your doctor to see if this trial is right for you.